An electronic patient-reported outcome symptom monitor: the Chinese experience with rapid development of a ready-to-go symptom monitor.

Publication date: Oct 29, 2024

Monitoring symptoms is crucial for the early detection of disease progression and timely intervention, which is essential for reducing severe cases and mortality rates in rapidly spreading pandemics, such as COVID-19. Therefore, during infectious disease pandemics, the rapid development of real-time symptom monitoring platforms is essential. This study aimed to explore the urgent development process of an electronic system for patient-reported outcome monitoring in emergency situations. The development of the electronic patient-reported outcome COVID-19 symptom monitoring platform (ePRO-CoV-SM) included the following steps: (1) modifying an electronic patient-reported outcome symptom-reporting platform to assess patients with COVID-19 and validating its feasibility and sensitivity for longitudinal symptom measurement; (2) updating the system to accommodate the newly emerged severe acute respiratory syndrome coronavirus 2 BA. 2.2 variant; and (3) applying it in real-world settings. Literature review, expert consultation, and subject-group discussions were used to develop symptom items. Response rate and missing item rate were used as validation indicators for ePRO-CoV-SM. The ePRO-CoV-SM (2. 0) consists of a core set of symptom items, a WeChat mini program, an online project design backend, a management and communication front, and a database. During the 2020 verification, the response rate of ePRO symptom monitoring reached 89. 47% and the item missing rate was 0. 33%, the monitoring revealed that a considerable number of asymptomatic patients were experiencing undesirable symptoms during the isolation period. In its real-world application in 2022, the response rate was 85. 93% and the item missing rate was 4. 84%, the monitoring found the symptom burden was higher in the younger group (18-40 years old) than in the older group (40-67 years old), and over 30% of patients reported symptoms such as cough (36. 08%), dry mouth (35. 67%), sleep disorders (32. 27%), appetite loss (32. 17%), and sputum (30. 79%) during the isolation period. Electronic patient-reported outcome measurement was demonstrated to be sensitive and feasible for monitoring symptoms in patients with COVID-19. By integrating smartphone-based data collection with real-time online data transmission and secure data storage using Secure Sockets Layer encryption, an electronic platform for monitoring critical symptoms can be rapidly established in emergency situations.

Open Access PDF

Concepts Keywords
Chinese Adolescent
Coronavirus Adult
Expert China
Smartphone COVID-19
COVID-19
Electronic Patient-Reported Outcome
Electronic platform
Female
Humans
Male
Middle Aged
SARS-CoV-2
Symptom
Symptom Assessment

Semantics

Type Source Name
disease IDO symptom
disease MESH disease progression
disease IDO intervention
disease MESH COVID-19
disease MESH infectious disease
pathway REACTOME Infectious disease
disease IDO process
disease MESH emergency
disease MESH symptom burden
disease MESH sleep disorders
pathway REACTOME Reproduction
drug DRUGBANK (S)-Des-Me-Ampa
drug DRUGBANK Coenzyme M
disease MESH dyspnea
disease MESH sore throat
disease MESH symptom worsening
drug DRUGBANK Alpha-1-proteinase inhibitor
drug DRUGBANK Tretamine
drug DRUGBANK Etoperidone
drug DRUGBANK Trestolone
pathway REACTOME Translation
disease IDO site
disease MESH infections
disease IDO infection
drug DRUGBANK Ethionamide
disease MESH Pneumonia
disease MESH Asymptomatic infections
disease IDO nucleic acid
disease MESH abnormalities
disease MESH anxiety
disease MESH chest pain
disease MESH joint pain
disease MESH confusion
disease MESH memory loss
pathway REACTOME Release
drug DRUGBANK Indoleacetic acid
drug DRUGBANK Spinosad
drug DRUGBANK Guanosine
drug DRUGBANK Ranitidine
disease MESH cancer

Original Article

(Visited 1 times, 1 visits today)